New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2013
07:17 EDTPACB, ILMN, FLDM, LIFELeerink to host a tour
Genomics Lab Tour consists of a tour of the Kansas University Medical Center's Genomics Lab and discusses the demand for DNA sequencing technologies, interest in new products, impact of funding constraints and DNA sequencing in the clinic. Relevant covered companies include Illumina, Life Technologies, Fluidigm and Pacific Biosciences. The tour is in Kansas City, Kansas and starts at 2 pm on March 27.
News For ILMN;LIFE;FLDM;PACB From The Last 14 Days
Check below for free stories on ILMN;LIFE;FLDM;PACB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 14, 2014
07:04 EDTFLDMFluidigm upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Fluidigm to Outperform citing reasonable consensus revenue estimates and strong demand for single cell gene expression analysis tools. The firm has a $52 price target for shares.
April 9, 2014
08:58 EDTILMNIllumina not targeted by new Chinese regulations, says Janney Capital
Subscribe for More Information
08:24 EDTFLDMPiper Jaffray's medtech analysts hold an analyst/industry conference call
The MedTech Analyst Team focuses on Piper Jaffray's covered universe from the perspective of Technical Analyst Johnson ahead of 1Q14 earnings results on an Analyst/Industry conference call to be held on April 11 at 10 am.
April 7, 2014
07:44 EDTFLDMMarketo to hold a summit
Subscribe for More Information
07:30 EDTILMNIllumina weakness creates buying opportunity, says Wells Fargo
Wells Fargo believes that the recent decline in Illumina's stock is mostly related to its correlation with biotech indices, and the firm sees this correlation as "a technical rather than a fundamental phenomenon." The firm believes that demand for the company's HiSeq, MiSeq, and HiSeq X instruments are strong, and it now identifies the stock as its top pick in the tools space. It increased its price target on the shares to $170-175 from $155-$160.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use